股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 526,579,084 | | 1,658,000 | | 528,237,084 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 526,579,0 ...

智通财经APP讯，堃博医疗-B(02216)公布，于2025年12月29日，该公司全资附属Broncus China Holding Corporation拟向启明医疗(香港)有限公司收购Valgen Holding Corporation15.78万股B系列优先股，占目标 公司截至本公告日期按全面摊薄及转换基准计算的发行在外股份的1.05%，总代价1500万美元。目标集 团主要从事提供二尖瓣反流及三尖瓣反流等疾病的系统解决方案。其产品包括二尖瓣修复装置 DragonFly™(经股静脉途径)及三尖瓣修复装置DragonFly-TTM。 鉴于结构性心脏病与肺部疾病之间存在相似性及关联性，董事会相信，收购事项提供了让集团得以实现 心肺疾病综合诊断及治疗的宝贵机会。凭借公司在慢性阻塞性肺病方面的专业知识，与目标集团的合作 将使集团能够为建立心肺疾病综合诊断和治疗平台奠定坚实基础。此外，由于结构性心脏病及肺部疾病 的治疗均涉及介入疗法，故收购事项亦为集团提供了提升其研发能力的机会，将其结构性心脏病的治疗 技术应用于肺部疾病的治疗，反之亦然。 ...

堃博医疗-B(02216)公布，于2025年12月29日，该公司全资附属Broncus China Holding Corporation拟向启 明医疗(香港)有限公司收购Valgen Holding Corporation15.78万股B系列优先股，占目标公司截至本公告日 期按全面摊薄及转换基准计算的发行在外股份的1.05%，总代价1500万美元。目标集团主要从事提供二 尖瓣反流及三尖瓣反流等疾病的系统解决方案。其产品包括二尖瓣修复装置DragonFly (经股静脉途径) 及三尖瓣修复装置DragonFly-TTM。 鉴于结构性心脏病与肺部疾病之间存在相似性及关联性，董事会相信，收购事项提供了让集团得以实现 心肺疾病综合诊断及治疗的宝贵机会。凭借公司在慢性阻塞性肺病方面的专业知识，与目标集团的合作 将使集团能够为建立心肺疾病综合诊断和治疗平台奠定坚实基础。此外，由于结构性心脏病及肺部疾病 的治疗均涉及介入疗法，故收购事项亦为集团提供了提升其研发能力的机会，将其结构性心脏病的治疗 技术应用于肺部疾病的治疗，反之亦然。 ...

鉴于结构性心脏病与肺部疾病之间存在相似性及关联性，董事会相信，收购事项提供了让集团得以实现 心肺疾病综合诊断及治疗的宝贵机会。凭藉公司在慢性阻塞性肺病方面的专业知识，与目标集团的合作 将使集团能够为建立心肺疾病综合诊断和治疗平台奠定坚实基础。 目标公司Valgen Holding Corporation为一家根据开曼群岛法律注册成立及存续的获豁免公司。目标集团 主要从事提供二尖瓣反流及三尖瓣反流等疾病的系统解决方案。其产品包括二尖瓣修复装置 DragonFly™(经股静脉途径)及三尖瓣修复装置DragonFly-T™。 格隆汇12月29日丨堃博医疗-B(02216.HK)公告，于2025年12月29日，买方Broncus China Holding Corporation(公司的全资附属公司)与卖方啓明医疗(香港)有限公司订立股份转让协议，据此，卖方有条 件同意出售，而买方有条件同意购买目标股份(占目标公司Valgen Holding Corporation截至本公告日期按 全面摊薄及转换基准计算的发行在外股份的1.05%，总代价为1500万美元(相等于约1.17亿港元)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 Broncus Holding Corporation 於2025年12月29日，買方（本公司的全資附屬公司）與賣方訂立股份轉讓協議， 據此，賣方有條件同意出售，而買方有條件同意購買目標股份（佔目標公司截 至本公告日期按全面攤薄及轉換基準計算的發行在外股份的1.05%，總代價為 15,000,000美元（相等於約116.6百萬港元）。 上市規則的涵義 由於與收購事項相關的最高適用百分比率（定義見上市規則）超過5%但全部低於 25%，故收購事項及其項下擬進行的交易構成本公司一項須予披露交易，須根 據上市規則第14章遵守公告及申報規定。 股東及潛在投資者應注意，收購事項須待交割條件獲達成後方可作實，且未必 一定會完成。股東及潛在投資者於買賣本公司證券時務請審慎行事。 收購事項 於2025年12月29日，買方（本公司的全資附屬公司）與賣方訂立股份轉讓協議， 據此，賣方有條件同意出售，而買方有條件同意購買目標股 ...

Core Viewpoint - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award recognizes outstanding investor relations (IR) teams of listed companies for their significant contributions to industry transformation and development [4]. Group 1: Award Announcement - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award was presented during the "Technology Empowerment · Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1]. - Ten companies were awarded the "Annual Excellence IR Team (Small and Medium Market Capitalization)" award, including Beikang Medical-B (02170.HK), Gushengtang (02273.HK), Huitongda Network (09878.HK), Jinxin Fertility (01951.HK), Kunbo Medical-B (02216.HK), Lianlian Digital (02598.HK), Qingsi Games (06633.HK), TCL Electronics (01070.HK), Yaxin Technology (01675.HK), and Zhaoke Ophthalmology-B (06622.HK) [1]. Group 2: Evaluation Criteria - The award evaluation focused on the construction of communication channels between IR teams and investors, emphasizing the importance of long-term perspectives on companies' overall performance [4]. - The selection process involved quantitative data analysis and expert review to determine the final results [4]. Group 3: Broader Context - Gelonghui aims to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 ...

Fundraising and Allocation - The total amount raised from the subscription is approximately HKD 326.9 million, with a net amount of about HKD 326.5 million after expenses, equivalent to a net issue price of approximately HKD 3.106 per share[6]. - 30% of the net proceeds (approximately HKD 98.0 million) will be allocated for the development and commercialization of the targeted lung denervation system (TLD system), covering technology iteration, clinical trials, and marketing[6]. - 35% of the net proceeds (approximately HKD 114.2 million) will fund the key technology development for the natural orifice flexible surgical robot, with clinical trials expected to be completed by 2029[6]. - 20% of the net proceeds (approximately HKD 65.3 million) will be used to establish an overseas headquarters in Ireland, focusing on obtaining overseas regulatory approvals and commercializing core products[6]. - 15% of the net proceeds (approximately HKD 49.0 million) will be allocated for the company's working capital and other general corporate purposes, expected to be fully utilized by 2028[6]. Regulatory and Operational Updates - The company is currently in the approval process for necessary consents related to the subscription agreement, with submissions made to the relevant regulatory authorities in China[4]. - The company plans to provide further announcements regarding the completion of the subscription at an appropriate time[5]. - The overseas headquarters will integrate and coordinate existing overseas operations, enhancing management of international business activities[6]. - The company aims to commercialize the BroncAblate® system in China by the first half of 2025, following approval from the National Medical Products Administration (NMPA)[6]. Executive Compensation - The company has not granted restricted share units to any of the top five highest-paid individuals for the year ending December 31, 2024, except for the executive director and CEO Xu Hong[7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 堃博医疗控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02216 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 ...

Core Viewpoint - Kubo Medical (02216) has seen a significant increase in stock price, rising over 9% during trading and currently up 5.86% at HKD 3.25, with a trading volume of HKD 11.79 million [1] Group 1: Company Actions - Kubo Medical announced plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, representing a premium of approximately 1.3% over the previous trading day's closing price [1] - The net proceeds from this issuance are expected to be around HKD 327 million, which will be used for potential acquisitions in the medical device industry to continue expanding the product portfolio [1] - The company is actively seeking potential acquisition targets within the medical device sector and is currently in discussions with various parties [1] Group 2: Strategic Partnerships - Notably, Ying Tai Medical (01501) plans to invest approximately HKD 283 million to subscribe for about 91.09 million shares of Kubo Medical [1] - The announcement highlights that Kubo Medical has a rich product line in the non-vascular interventional field, and the subscription will further enhance the company's strategic positioning in this area [1]